Regenxbio Inc. (RGNX) Shares Up 4%
Shares of Regenxbio Inc. (NASDAQ:RGNX) shot up 4% during mid-day trading on Monday . The stock traded as high as $12.11 and last traded at $11.96, with a volume of 145,367 shares traded. The stock had previously closed at $11.50.
A number of analysts have weighed in on RGNX shares. Zacks Investment Research lowered shares of Regenxbio from a “hold” rating to a “sell” rating in a research report on Friday. Piper Jaffray Cos. restated a “buy” rating and issued a $33.00 target price on shares of Regenxbio in a research report on Tuesday, July 5th. Finally, Chardan Capital restated a “buy” rating on shares of Regenxbio in a research report on Tuesday, May 10th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Regenxbio has an average rating of “Buy” and an average price target of $28.35.
The stock’s 50-day moving average is $8.42 and its 200-day moving average is $10.92. The firm’s market capitalization is $325.52 million.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.02. On average, analysts forecast that Regenxbio Inc. will post ($2.31) EPS for the current fiscal year.
An institutional investor recently raised its position in Regenxbio stock. RS Investment Management Co. LLC boosted its position in Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned approximately 2.84% of Regenxbio worth $12,393,000 at the end of the most recent quarter.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.